PROFIT JUMPS FOR FOREST LABS. Pharmaceutical maker Forest Laboratories Inc. - a Manhattan company with Long Island operations - reported yesterday a 34 percent increase in profits for the quarter that ended June 30. Forest saw a 27 percent jump in sales of Namenda, its drug that treats Alzheimer's disease, to $191.7 million in the quarter. But sales of Forest's anti-depressant Lexapro did not grow as much as some analysts expected. Lexapro sales increased 9 percent, to $552 million; analysts' sales estimates for the drug were as high as $567 million. Forest's net income rose 34 percent, to $268.2 million, or 83 cents per share, compared with $200.6 million, or 62 cents per share, in the same quarter a year ago. Revenue increased 14 percent, to $928.3 million. Howard Solomon, Forest chairman and chief executive, said the company had positive results for a Phase 3 clinical trial of its fibromyalgia drug milnacipran. Solomon said, however, that in a study, a stroke drug, desmoteplase, did not perform as expected. Forest's shares closed down $1.17 yesterday to $45.46. - KATHLEEN KERR

GOOGLE OFFERS TO RUN SEARCHES FOR WEB SITES. Google Inc. is offering to run the search engines of small Web sites for as little as $100 per year, marking the company's latest attempt to make more money from technology that already steers much of the Internet's traffic. The service scheduled to be unveiled yesterday is aimed at the millions of Web sites that either don't have search engines or are unhappy with the quality of their current search results, said Nitin Mangtani, a Google product manager. The price for Google's "Custom Search Business Edition" will start at $100 annually to sift through up to 5,000 Web pages. Larger Web sites can pay Google $500 annually to search up to 50,000 Web pages.